Scarica l'app Stockscreener
4.21
0.47%
-0.02
Adc Therapeutics Sa Borsa (ADCT) Ultime notizie
ADC Therapeutics (NYSE:ADCT) Sees Large Volume IncreaseStill a Buy? - MarketBeat
ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call Transcript - MSN
ADC Therapeutics SA Stock Analysis and ForecastHigh Beta Stocks & Predict Price Movements With AI Precision - earlytimes.in
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire
Officer Graham Surrenders 49,508 Of ADC Therapeutics SA [ADCT] - TradingView — Track All Markets
ADC Therapeutics (NYSE: ADCT) CEO reports 233,146-share tax withholding - Stock Titan
ADC Therapeutics (ADCT) CMO has 41,068 shares withheld for RSU taxes - Stock Titan
ADC Therapeutics (ADCT) CAO reports 7,140 shares withheld for RSU tax and holds 70,757 - Stock Titan
ADC Therapeutics (ADCT) CLO Peter Graham reports tax share withholding - Stock Titan
ADC Therapeutics (ADCT) CFO reports 53,236-share tax withholding from RSU vesting - Stock Titan
ADC Therapeutics (ADCT) files S-3/A Amendment No. 1 to add new auditor consent - Stock Titan
Adc Therapeutics SA (ADCT) expanding its growth trajectory ahead - setenews.com
ADC Therapeutics reports promising LOTIS-7 trial results - MSN
Is ADC Therapeutics SA a good long term investmentCup and Handle Formations & Discover High-Return Stocks Before They Boom - earlytimes.in
Will Fed Rate Hikes Affect Voltaire Leasing Finance Limited Stocks OutlookPrice Volatility Patterns & Target Triple-Digit Stock Opportunities - earlytimes.in
ADC Therapeutics Reports Promising LOTIS-7 Trial Results - TipRanks
ADC Therapeutics Updates LOTIS-7 Trial Data - TradingView — Track All Markets
[8-K] ADC Therapeutics SA Reports Material Event | ADCT SEC FilingForm 8-K - Stock Titan
Is ADC Therapeutics SA Common Shares stock attractive post correction2025 Institutional Moves & Growth Focused Investment Plans - Newser
Is ADC Therapeutics SA stock oversold or undervalued2025 Market WrapUp & Scalable Portfolio Growth Ideas - Newser
What momentum indicators show for ADC Therapeutics SA stockShare Buyback & Accurate Entry and Exit Point Alerts - Newser
Will ADC Therapeutics SA stock benefit from commodity pricesQuarterly Trade Summary & Daily Entry Point Alerts - Newser
How forex fluctuations impact ADC Therapeutics SA Common Shares stockPortfolio Performance Report & Reliable Intraday Trade Plans - Newser
Will ADC Therapeutics SA Common Shares stock boost dividends further2025 Analyst Calls & Capital Protection Trading Alerts - Newser
Can ADC Therapeutics SA stock deliver surprise earnings beatOptions Play & Long-Term Investment Growth Plans - Newser
Why Is ADC Therapeutics Plunging Today - Sahm
Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma - Yahoo Finance
ADC Therapeutics stock maintains Outperform rating at RBC on strong trial data - Investing.com India
ADC Therapeutics (NYSE:ADCT) Trading Up 6.5%Should You Buy? - MarketBeat
ADC Therapeutics stock falls after LOTIS-7 trial update By Investing.com - Investing.com Canada
ADC Therapeutics stock falls after LOTIS-7 trial update - Investing.com India
Crude Oil Gains 1%; Macy's Reports Strong Q3 Results - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ZYNLONTA-glofitamab combo shows 90% response rate in lymphoma trial By Investing.com - Investing.com Nigeria
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCLSlideshow (NYSE:ADCT) 2025-12-03 - Seeking Alpha
ADCT: LOTIS-7: Zynlonta plus glofitamab delivers high, durable CR rates and manageable safety in DLBCL - TradingView
ADC Therapeutics : (ADCT Webcast Presentation 120225) - marketscreener.com
ZYNLONTA-glofitamab combo shows 90% response rate in lymphoma trial - Investing.com India
ADC Therapeutics Says Updated Data for Drug Supports Potential Best-in-Class Regimen in Lymphoma Patients - marketscreener.com
ADCT: ZYNLONTA plus glofitamab delivers high response rates and manageable safety in r/r LBCL - TradingView
ADC Therapeutics announces updated data from Lotis-7 phase 1b clinical trial of Zynlonta - marketscreener.com
Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta - TradingView
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Fidelity
ADCT: LOTIS-7 Phase 1b trial update for ZYNLONTA plus glofitamab in r/r DLBCL set for Dec 3, 2025 - TradingView
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial - BioSpace
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - 富途牛牛
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):